Results 41 to 50 of about 19,753 (208)

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review

open access: yesJournal of Bone Oncology, 2015
Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor ...
Hampig Raphael Kourie   +5 more
doaj   +1 more source

Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2016
Introduction: Osteoporosis is still a under recognized entity in the population. Osteoporosis-related fractures can be prevented if people at risk can be screened, diagnosed and treated early.
Prem Kotian   +2 more
doaj   +1 more source

Lifestyle Management in Menopause: A Systematic Review of Women With Premature Ovarian Insufficiency

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective Premature ovarian insufficiency (POI), the loss of ovarian function before age 40, increases the risk of cardiovascular disease, low bone mineral density, dementia and psychological distress. Lifestyle interventions reduce chronic disease risk in other populations and, with hormone therapy, may improve health outcomes in POI.
Ladan Yeganeh   +4 more
wiley   +1 more source

Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound.

open access: yesPLoS ONE, 2015
Zoledronic acid, a highly potent nitrogen-containing bisphosphonate used for the treatment of pathological bone loss, is excreted unmetabolized via the kidney if not bound to the bone.
Anja Verhulst   +3 more
doaj   +1 more source

Clinical Practice Patterns in Bone Health Assessment and Management in Endogenous Cushing's Syndrome

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective Skeletal fragility is a common complication of endogenous Cushing's Syndrome (CS), although specific guidelines for managing bone health are lacking. This study aimed to assess clinicians' current engagement with bone health assessment and management in patients with endogenous CS. Design Retrospective‐cohort design. Patients Seventy‐
Preeshila Behary   +10 more
wiley   +1 more source

Soluble Sema4D From γδ T Cells Exerts Osteoblast Inhibition via Plexin‐B/mTOR Signalling Contributing to Pathogenesis of Bisphosphonate‐Related Osteonecrosis of the Jaws

open access: yesCell Proliferation, EarlyView.
Schematic summarizing the pathway of sSema4D from γδ T cells inhibiting osteoblast differentiation in BRONJ. ABSTRACT Bisphosphonate‐related osteonecrosis of the jaw (BRONJ) is a severe complication in patients undergoing long‐term bisphosphonate therapy, while our knowledge on the pathogenesis of BRONJ is far from sufficient.
Lingling Ou   +15 more
wiley   +1 more source

Efficacy and Safety of Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT This retrospective study evaluates the efficacy and safety of donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT) in children. We describe the long‐term use of preemptive, prophylactic, and therapeutic DLI with a gradual dose increase in half‐log increments.
Dinah Walther   +7 more
wiley   +1 more source

The Effect of Zoledronic Acid on BSP Expression and Methylation during Osteoblastic Differentiation of Mesenchymal Stem Cells [PDF]

open access: yesپیاورد سلامت, 2011
Background and Aim: Bone sialoprotein (BSP) is a specific marker of osteoblastic differentiation. In this research, the effect of Zoledronic Acid on BSP expression and methylation status during osteoblastic differentiation of mesenchymal stem cells (MSCs)
M Mahmodi Niya Meymand   +5 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy